☰

Jeffrey W. Johannes, Ph.D. - Publications

Affiliations: 
2005 Harvard University, Cambridge, MA, United States 
Area:
synthesis of natural products
Tree Info Similar researchers PubMed Report error

22/40 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Escobar RA, Johannes JW. A Unified and Practical Method for Carbon-Heteroatom Cross-Coupling using Nickel/Photo Dual Catalysis. Chemistry (Weinheim An Der Bergstrasse, Germany). PMID 32065838 DOI: 10.1002/Chem.202000052  0.313
2020 Howard RT, Hemsley P, Petteruti P, Saunders CN, Molina Bermejo JA, Scott JS, Johannes JW, Tate EW. Structure-guided design and in-cell target profiling of a cell-active target engagement probe for PARP inhibitors. Acs Chemical Biology. PMID 32017532 DOI: 10.1021/Acschembio.9B00963  0.371
2018 Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, Cidado J, Embrey KJ, Gangl E, Gibbons FD, Gregory GP, Hargreaves D, Hendricks JA, Johannes JW, Johnstone RW, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nature Communications. 9: 5341. PMID 30559424 DOI: 10.1038/S41467-018-07551-W  0.331
2018 Wang Z, Grosskurth SE, Cheung T, Petteruti P, Zhang J, Wang X, Wang W, Gharahdaghi F, Wu J, Su N, Howard RT, Mayo M, Widzowski D, Scott DA, Johannes JW, et al. Pharmacological inhibition of PARP6 triggers multipolar spindle formation and elicits therapeutic effects in breast cancer. Cancer Research. PMID 30297535 DOI: 10.1158/0008-5472.Can-18-1362  0.376
2018 Gingipalli L, Block MH, Bao L, Cooke E, Dakin LA, Denz CR, Ferguson AD, Johannes JW, Larsen NA, Lyne PD, Pontz TW, Wang T, Wu X, Wu A, Zhang HJ, et al. Discovery of 2,6-disubstituted pyrazine derivatives as inhibitors of CK2 and PIM kinases. Bioorganic & Medicinal Chemistry Letters. PMID 29559278 DOI: 10.1016/J.Bmcl.2018.03.018  0.388
2018 Leo E, Johannes J, Illuzzi G, Zhang A, Hemsley P, Bista MJ, Orme JP, Talbot VA, Narvaez AJ, Underwood E, Pike A, Nikkila JK, Riches L, Sweeney S, Gustafsson F, et al. Abstract LB-273: A head-to-head comparison of the properties of five clinical PARP inhibitors identifies new insights that can explain both the observed clinical efficacy and safety profiles Cancer Research. 78. DOI: 10.1158/1538-7445.Am2018-Lb-273  0.326
2018 Konev MO, McTeague TA, Johannes JW. Nickel-Catalyzed Photoredox-Mediated Cross-Coupling of Aryl Electrophiles and Aryl Azides Acs Catalysis. 8: 9120-9124. DOI: 10.1021/Acscatal.8B02954  0.341
2017 Johannes J, Denz CR, Su N, Wu A, Impastato AC, Mlynarski S, Varnes JG, Prince DB, Cidado J, Gao N, Haddrick M, Jones NH, Li S, Li X, Liu Y, et al. Structure Based Design of Selective Non-covalent CDK12 Inhibitors. Chemmedchem. PMID 29266803 DOI: 10.1002/Cmdc.201700695  0.394
2017 Johannes JW, Bates S, Beigie C, Belmonte MA, Breen J, Cao S, Centrella PA, Clark MA, Cuozzo JW, Dumelin CE, Ferguson AD, Habeshian S, Hargreaves D, Joubran C, Kazmirski S, et al. Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors. Acs Medicinal Chemistry Letters. 8: 239-244. PMID 28197319 DOI: 10.1021/Acsmedchemlett.6B00464  0.346
2017 Hird AW, Secrist JP, Adam A, Belmonte MA, Gangl E, Gibbons F, Hargreaves D, Johannes JW, Kazmirski SL, Kettle JG, Kurtz SE, Lamb ML, Packer MJ, Peng B, Stewart CR, et al. Abstract DDT01-02: AZD5991: A potent and selective macrocyclic inhibitor of Mcl-1 for treatment of hematologic cancers Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Ddt01-02  0.342
2016 Gu C, Lamb ML, Johannes JW, Sylvester MA, Eisman MS, Harrison RA, Hu H, Kazmirski S, Mikule K, Peng B, Su N, Wang W, Ye Q, Zheng X, Lyne PD, et al. Modulating the strength of hydrogen bond acceptors to achieve low Caco2 efflux for oral bioavailability of PARP inhibitors blocking centrosome clustering. Bioorganic & Medicinal Chemistry Letters. PMID 27578247 DOI: 10.1016/J.Bmcl.2016.08.030  0.31
2016 Oderinde MS, Jones NH, Juneau A, Frenette M, Aquila B, Tentarelli S, Robbins DW, Johannes JW. Highly Chemoselective Iridium Photoredox and Nickel Catalysis for the Cross-Coupling of Primary Aryl Amines with Aryl Halides. Angewandte Chemie (International Ed. in English). PMID 27436532 DOI: 10.1002/Anie.201604429  0.325
2016 Oderinde MS, Frenette M, Robbins DW, Aquila B, Johannes JW. Photoredox Mediated Nickel Catalyzed Cross-Coupling of Thiols With Aryl and Heteroaryl Iodides via Thiyl Radicals. Journal of the American Chemical Society. PMID 26840123 DOI: 10.1021/Jacs.5B11244  0.321
2016 Oderinde MS, Jones NH, Juneau A, Frenette M, Aquila B, Tentarelli S, Robbins DW, Johannes JW. Back Cover: Highly Chemoselective Iridium Photoredox and Nickel Catalysis for the Cross-Coupling of Primary Aryl Amines with Aryl Halides (Angew. Chem. Int. Ed. 42/2016) Angewandte Chemie International Edition. 55: 13350-13350. DOI: 10.1002/Anie.201607767  0.319
2016 Oderinde MS, Jones NH, Juneau A, Frenette M, Aquila B, Tentarelli S, Robbins DW, Johannes JW. Rücktitelbild: Highly Chemoselective Iridium Photoredox and Nickel Catalysis for the Cross-Coupling of Primary Aryl Amines with Aryl Halides (Angew. Chem. 42/2016) Angewandte Chemie. 128: 13546-13546. DOI: 10.1002/Ange.201607767  0.317
2015 Johannes JW, Almeida L, Daly K, Ferguson AD, Grosskurth SE, Guan H, Howard T, Ioannidis S, Kazmirski S, Lamb ML, Larsen NA, Lyne PD, Mikule K, Ogoe C, Peng B, et al. Discovery of AZ0108, an orally bioavailable phthalazinone PARP inhibitor that blocks centrosome clustering. Bioorganic & Medicinal Chemistry Letters. PMID 26546219 DOI: 10.1016/J.Bmcl.2015.10.079  0.366
2015 Johannes JW, Almeida L, Barlaam B, Boriack-Sjodin PA, Casella R, Croft RA, Dishington AP, Gingipalli L, Gu C, Hawkins JL, Holmes JL, Howard T, Huang J, Ioannidis S, Kazmirski S, et al. Pyrimidinone nicotinamide mimetics as selective tankyrase and wnt pathway inhibitors suitable for in vivo pharmacology. Acs Medicinal Chemistry Letters. 6: 254-9. PMID 25815142 DOI: 10.1021/Ml5003663  0.372
2014 Johannes JW, Chuaqui C, Cowen S, Devereaux E, Gingipalli L, Molina A, Wang T, Whitston D, Wu X, Zhang HJ, Zinda M. Discovery of 6-aryl-azabenzimidazoles that inhibit the TBK1/IKK-ε kinases. Bioorganic & Medicinal Chemistry Letters. 24: 1138-43. PMID 24462666 DOI: 10.1016/J.Bmcl.2013.12.123  0.409
2013 Vasbinder MM, Aquila B, Augustin M, Chen H, Cheung T, Cook D, Drew L, Fauber BP, Glossop S, Grondine M, Hennessy E, Johannes J, Lee S, Lyne P, Mörtl M, et al. Discovery and optimization of a novel series of potent mutant B-Raf(V600E) selective kinase inhibitors. Journal of Medicinal Chemistry. 56: 1996-2015. PMID 23398453 DOI: 10.1021/Jm301658D  0.357
2012 Wang T, Block MA, Cowen S, Davies AM, Devereaux E, Gingipalli L, Johannes J, Larsen NA, Su Q, Tucker JA, Whitston D, Wu J, Zhang HJ, Zinda M, Chuaqui C. Discovery of azabenzimidazole derivatives as potent, selective inhibitors of TBK1/IKKε kinases. Bioorganic & Medicinal Chemistry Letters. 22: 2063-9. PMID 22305584 DOI: 10.1016/J.Bmcl.2012.01.018  0.395
2011 Cooke E, Alimzhanov M, Almeida L, Bao L, Bedian V, Brown J, Deng C, Denz C, Gingipalli L, Johannes J, Kazmirski S, Lamb M, Liu Z, Racicot V, Su N, et al. Abstract 5196: The discovery of small molecule inhibitors of Tankyrases 1 and 2, which modulate Axin homeostasis and inhibit Wnt signalingin vivo Cancer Research. 71: 5196-5196. DOI: 10.1158/1538-7445.Am2011-5196  0.351
2005 Johannes JW, Wenglowsky S, Kishi Y. Biomimetic macrocycle-forming Diels-Alder reaction of an iminium dienophile: synthetic studies directed toward gymnodimine. Organic Letters. 7: 3997-4000. PMID 16119951 DOI: 10.1021/Ol051553N  0.412
Low-probability matches (unlikely to be authored by this person)
2015 Oderinde MS, Varela-Alvarez A, Aquila B, Robbins DW, Johannes JW. Effects of Molecular Oxygen, Solvent, and Light on Iridium-Photoredox/Nickel Dual-Catalyzed Cross-Coupling Reactions. The Journal of Organic Chemistry. 80: 7642-51. PMID 26140623 DOI: 10.1021/Acs.Joc.5B01193  0.298
2018 Denz C, Johannes J, Yao Y, Kulkarni M, Dulak A, Guan N, Su N, Lamb M, Fawell S, Guichard S. Abstract B172: Identification of a novel RNA processing mechanism of intronic readthrough to a transcriptional stop leading to truncated transcript expression, including FANCI and ATM, upon CDK12 inhibition Molecular Cancer Therapeutics. 17. DOI: 10.1158/1535-7163.Targ-17-B172  0.296
2019 Balazs AYS, Carbajo RJ, Davies NL, Dong Y, Hird AW, Johannes JW, Lamb ML, McCoull W, Raubo P, Robb GR, Packer MJ, Chiarparin E. Free Ligand 1D NMR Conformational Signatures to Enhance Structure Based Drug Design of a Mcl-1 inhibitor (AZD5991) and other Synthetic Macrocycles. Journal of Medicinal Chemistry. PMID 31361481 DOI: 10.1021/Acs.Jmedchem.9B00716  0.285
2017 Gu C, Wen S, Doig P, Gangl E, Zheng X, Wang Y, Johannes JW. Mouse Red Blood Cell Mediated Rare Xenobiotic Phosphorylation of a Drug Molecule Not Intended To Be a Kinase Substrate. Drug Metabolism and Disposition: the Biological Fate of Chemicals. PMID 28986473 DOI: 10.1124/Dmd.117.076869  0.281
2016 Holmes JL, Almeida L, Barlaam B, Croft RA, Dishington AP, Gingipalli L, Hassall LA, Hawkins JL, Ioannidis S, Johannes JW, Mcguire TM, Moore JE, Patel A, Pike KG, Pontz T, et al. Synthesis of Novel Hydroxymethyl-Substituted Fused Heterocycles Synthesis (Germany). DOI: 10.1055/S-0035-1561355  0.273
2017 Johannes JW, Bates S, Beigie C, Belmonte MA, Breen J, Cao S, Centrella PA, Clark MA, Cuozzo JW, Dumelin CE, Ferguson AD, Habeshian S, Hargreaves D, Joubran C, Kazmirski S, et al. Correction to "Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors". Acs Medicinal Chemistry Letters. 8: 1204. PMID 29152055 DOI: 10.1021/Acsmedchemlett.7B00397  0.266
2020 Struble TJ, Alvarez JC, Brown S, Chytil M, Cisar J, DesJarlais R, Engkvist O, Frank SA, Greve DR, Griffin DJ, Hou X, Johannes JW, Kreatsoulas C, Lahue B, Mathea M, et al. Current and Future Roles of Artificial Intelligence in Medicinal Chemistry Synthesis. Journal of Medicinal Chemistry. PMID 32243158 DOI: 10.1021/Acs.Jmedchem.9B02120  0.256
2021 Johannes JW, Balazs A, Barratt D, Bista M, Chuba MD, Cosulich S, Critchlow SE, Degorce SL, Di Fruscia P, Edmondson SD, Embrey K, Fawell S, Ghosh A, Gill SJ, Gunnarsson A, et al. Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}--methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs. Journal of Medicinal Chemistry. PMID 34570508 DOI: 10.1021/acs.jmedchem.1c01012  0.249
2017 Oderinde MS, Johannes JW. Practical Syntheses of [2,2’-bipyridine]bis[3,5-difluoro-2-[5-(trifluoromethyl)-2-pyridinyl]phenyl]iridium(III) hexafluorophosphate, [Ir{dF(CF3)ppy}2(bpy)]PF6 and [4,4’-bis(tert-butyl)-2,2’-bipyridine]bis[3,5-difluoro-2-[5-(trifluoromethyl)-2-pyridinyl]phenyl]iridium(III) hexafluorophosphate, [Ir{dF(CF3)ppy}2(dtbbpy)]PF6 Organic Syntheses. 94: 77-92. DOI: 10.1002/0471264229.Os094.07  0.247
2023 Hargreaves D, Carbajo RJ, Bodnarchuk MS, Embrey K, Rawlins PB, Packer M, Degorce SL, Hird AW, Johannes JW, Chiarparin E, Schade M. Design of rigid protein-protein interaction inhibitors enables targeting of undruggable Mcl-1. Proceedings of the National Academy of Sciences of the United States of America. 120: e2221967120. PMID 37186857 DOI: 10.1073/pnas.2221967120  0.236
2023 Chrisman CH, Kudisch M, Puffer KO, Stewart TK, Lamb YML, Lim CH, Escobar R, Thordarson P, Johannes JW, Miyake GM. Halide Noninnocence and Direct Photoreduction of Ni(II) Enables Coupling of Aryl Chlorides in Dual Catalytic, Carbon-Heteroatom Bond-Forming Reactions. Journal of the American Chemical Society. PMID 37204458 DOI: 10.1021/jacs.3c02784  0.191
2022 Illuzzi G, Staniszewska AD, Gill SJ, Pike A, McWilliams L, Critchlow SE, Cronin A, Fawell S, Hawthorne G, Jamal K, Johannes J, Leonard E, Macdonald R, Maglennon G, Nikkil J, et al. Preclinical characterization of AZD5305, a next generation, highly selective PARP1 inhibitor and trapper. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 35929986 DOI: 10.1158/1078-0432.CCR-22-0301  0.19
2022 Gravatt CS, Johannes JW, King ER, Ghosh A. Photoredox-Mediated, Nickel-Catalyzed Trifluoromethylthiolation of Aryl and Heteroaryl Iodides. The Journal of Organic Chemistry. 87: 8921-8927. PMID 35786936 DOI: 10.1021/acs.joc.2c00631  0.183
2021 Balazs AYS, Carbajo RJ, Davies NL, Dong Y, Hird AW, Johannes JW, Lamb ML, McCoull W, Raubo P, Robb GR, Packer MJ, Chiarparin E. Correction to "Free Ligand 1D NMR Conformational Signatures To Enhance Structure Based Drug Design of a Mcl-1 Inhibitor (AZD5991) and Other Synthetic Macrocycles". Journal of Medicinal Chemistry. PMID 33646774 DOI: 10.1021/acs.jmedchem.1c00273  0.175
2021 Escobar RA, Johannes JW. Reductive Radical Conjugate Addition of Alkyl Electrophiles Catalyzed by a Cobalt/Iridium Photoredox System. Organic Letters. PMID 34270268 DOI: 10.1021/acs.orglett.1c02114  0.157
2021 Escobar RA, Johannes JW. Reductive Radical Conjugate Addition of Alkyl Electrophiles Catalyzed by a Cobalt/Iridium Photoredox System. Organic Letters. PMID 34270268 DOI: 10.1021/acs.orglett.1c02114  0.157
2023 Staniszewska AD, Pilger D, Gill SJ, Jamal K, Bohin N, Guzzetti S, Gordon J, Hamm G, Mundin G, Illuzzi G, Pike A, McWilliams L, Maglennon G, Rose J, Hawthorne G, ... ... Johannes JW, et al. Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 37967136 DOI: 10.1158/1078-0432.CCR-23-2094  0.128
2024 Erickson EC, You I, Perry G, Dugourd A, Donovan KA, Crafter C, Johannes JW, Williamson S, Moss JI, Ros S, Ziegler RE, Barry ST, Fischer ES, Gray NS, Madsen RR, et al. Multiomic profiling of breast cancer cells uncovers stress MAPK-associated sensitivity to AKT degradation. Science Signaling. 17: eadf2670. PMID 38412255 DOI: 10.1126/scisignal.adf2670  0.12
Hide low-probability matches.